Why cancer drug programs need human mass balance studies
Historically, drug programs for oncology and other rapidly fatal diseases didn’t include mass balance studies…
CertaraSeptember 23, 2024
Certara Launches Early Development Solution to Reduce Failure Rates in Early-Stage Drug Development
New solution offers early-stage developers a dedicated team of experts with combined experience in end-to-end…
CertaraSeptember 19, 2024
A close examination of BCRP’s role in lactation and methods for predicting drug distribution into milk
The article, authored by Caroline Sychterz, Hong Shen, Yueping Zhang, Michael Sinz, Amin Rostami-Hodjegan, Brian…
CertaraSeptember 18, 2024
Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug
Preclinical research on the trispecific antibody, ISB 2001, published in Nature Cancer leveraged virtual trials to…
CertaraSeptember 18, 2024
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells
Abstract Despite recent advances in immunotherapies targeting single tumor-associated antigens, patients with multiple myeloma eventually…
CertaraSeptember 18, 2024
Towards a Platform Quantitative Systems Pharmacology (QSP) Model for Preclinical to Clinical Translation of Antibody Drug Conjugates (ADCs)
Abstract A next generation multiscale quantitative systems pharmacology (QSP) model for antibody drug conjugates (ADCs)…
CertaraSeptember 18, 2024
A Next Generation Mathematical Model for the in vitro to Clinical Translation of T-cell Engagers
Abstract T-cell engager (TCE) molecules activate the immune system and direct it to kill tumor…
CertaraSeptember 18, 2024
Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions
Abstract Incorporating an early evaluation of dosing requirements is crucial for assessing the viability of…
CertaraSeptember 18, 2024
